<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">IJPN</journal-id><journal-title-group><journal-title>International Journal of Psychiatry and Neurology</journal-title></journal-title-group><issn pub-type="epub">2166-5788</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/IJPN.2020.92003</article-id><article-id pub-id-type="publisher-id">IJPN-35419</article-id><article-categories><subj-group subj-group-type="heading"><subject>IJPN20200200000_16701232.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  内源性大麻素在神经退行性疾病中的作用研究进展
  Review of Research Progress on Endocannabinoids in Neurodegenerative Diseases
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>朱</surname><given-names>时钰</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陆</surname><given-names>永利</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>红卫</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>三峡大学医学院生理与病理生理学系，湖北 宜昌</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>21</day><month>04</month><year>2020</year></pub-date><volume>09</volume><issue>02</issue><fpage>20</fpage><lpage>25</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  神经退行性疾病(Neurodegenerative disease)是一类以神经元变性病变为基础的缓慢进展性疾病的总称，主要包括阿尔茨海默病(Alzheimer’s disease, AD)、帕金森病(Parkinson’s disease, PD)及肌萎缩侧索硬化症(amyotrophic lateral sclerosis, ALS)等。最近的研究发现内源性大麻素系统(endocannabinoid system, eCBs)可能是一种保护神经元免受伤害性刺激的内源性系统，对神经退行性疾病的病程有预防治疗作用。本文综述了eCBs对AD、PD及ALS的保护作用的几个方面，旨在为神经退行性疾病的治疗开辟新的策略和思路。
   Neurodegenerative diseases are characterized by slowly progressive degeneration and/or death of nerve cells. Examples of neurodegenerative diseases contain Alzheimer’s disease (AD), Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS). Recent studies reveal that endocannabinoid system may be an endogenous system that protects neurons from harmful stimuli and may have a preventive and therapeutic effect on the neurodegenerative diseases. Here we summarized several aspects of the eCBs protective effect of the AD, PD and ALS, aiming at providing promising thera-peutic targets and new strategy for neurodegenerative diseases.
 
</p></abstract><kwd-group><kwd>内源性大麻素，大麻素受体，神经退行性疾病, Endocannabinoids</kwd><kwd> Endocannabinoid Receptor</kwd><kwd> Neurodegenerative Diseases</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>内源性大麻素在神经退行性疾病中的作用研究进展<sup> </sup></title><p>朱时钰<sup>*</sup>，陆永利，杨红卫<sup>#</sup></p><p>三峡大学医学院生理与病理生理学系，湖北 宜昌</p><disp-formula id="hanspub.35419-formula13"><graphic xlink:href="//html.hanspub.org/file/2-2240120x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2020年2月24日；录用日期：2020年4月29日；发布日期：2020年5月6日</p><disp-formula id="hanspub.35419-formula14"><graphic xlink:href="//html.hanspub.org/file/2-2240120x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>神经退行性疾病(Neurodegenerative disease)是一类以神经元变性病变为基础的缓慢进展性疾病的总称，主要包括阿尔茨海默病(Alzheimer’s disease, AD)、帕金森病(Parkinson’s disease, PD)及肌萎缩侧索硬化症(amyotrophic lateral sclerosis, ALS)等。最近的研究发现内源性大麻素系统(endocannabinoid system, eCBs)可能是一种保护神经元免受伤害性刺激的内源性系统，对神经退行性疾病的病程有预防治疗作用。本文综述了eCBs对AD、PD及ALS的保护作用的几个方面，旨在为神经退行性疾病的治疗开辟新的策略和思路。</p><p>关键词 :内源性大麻素，大麻素受体，神经退行性疾病</p><disp-formula id="hanspub.35419-formula15"><graphic xlink:href="//html.hanspub.org/file/2-2240120x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/2-2240120x8_hanspub.png" /> <img src="//html.hanspub.org/file/2-2240120x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>神经退行性疾病(Neurodegenerative diseases)是一类以神经元变性病变为基础的缓慢进展性疾病的总称，主要包括阿尔茨海默病(Alzheimer’s disease, AD)、帕金森病(Parkinson’s disease, PD)及肌萎缩侧索硬化症(amyotrophic lateral sclerosis, ALS)等。虽然目前很多药物能缓解其症状，却不能有效地抑制病情的进一步恶化。研究表明内源性大麻素(endogenous cannabinoids, eCBs)与AD、PD及ALS等神经退行性疾病的病程联系密切，活化的eCBs具有抗神经元凋亡、抗氧化应激及抗炎等功效，并最终改善学习和记忆能力。</p></sec><sec id="s4"><title>2. 内源性大麻素系统</title><p>eCBs系统是二十碳不饱和脂肪酸的内源性代谢产物，由eCBs配体、受体及其特异性代谢酶组成。2-花生四烯酸甘油(2-arachidonoyl-glycerol, 2-AG)与四烯酸氨基乙醇(anandamide, AEA)是eCBs配体中研究最为广泛和深入的两种，它们通过激活G-蛋白偶联的大麻素受体CB1或CB2发挥效应。CB1受体主要存在神经系统中，位于神经元的突触前膜，为突触后膜释放的eCBs所激活 [<xref ref-type="bibr" rid="hanspub.35419-ref1">1</xref>] [<xref ref-type="bibr" rid="hanspub.35419-ref2">2</xref>]，而CB2受体则主要分布在免疫系统中，起免疫调节作用 [<xref ref-type="bibr" rid="hanspub.35419-ref2">2</xref>]。近来的证据表明CB2受体也存在于脑的星型胶质细胞和脑干神经元，提示CB2受体可能参与脑的生理和病理过程 [<xref ref-type="bibr" rid="hanspub.35419-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.35419-ref3">3</xref>]。2-AG由二酯酰甘油脂肪酶催化二酯酰甘油产生，并在单酯酰甘油脂肪酶作用下水解为花生四烯酸；而AEA是N-花生四烯酸磷脂酰乙醇胺经由磷脂酶D催化合成，并在脂肪酰胺水解酶作用下水解为花生四烯酸。研究表明2-AG和AEA通过CB1和CB2受体参与哺乳动物组织的各种生理和病理过程。eCBs可根据细胞需求产生，代谢型受体、离子型受体或二者同时作用均能促进其合成，与CB受体结合后抑制突触前膜Ca<sup>2+</sup>内流，通过抑制囊泡与突触前膜的融合影响神经递质释放 [<xref ref-type="bibr" rid="hanspub.35419-ref2">2</xref>] [<xref ref-type="bibr" rid="hanspub.35419-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.35419-ref5">5</xref>]。</p></sec><sec id="s5"><title>3. eCBs系统对AD的保护作用</title><p>AD的病理性特征主要表现为老年斑和tau蛋白的高度磷酸化。淀粉样前体蛋白通过β-和γ-分泌酶裂解生成Aβ，Aβ累积形成老年斑损害神经元，从而导致认知功能和学习记忆的衰退 [<xref ref-type="bibr" rid="hanspub.35419-ref6">6</xref>]。</p><p>增加Aβ的转运或促进Aβ的吞噬是降低颅内Aβ水平的一个重要途径。部分AD患者是由于Aβ通过血脑屏障的清除率减少所引起，因此增加颅内eCBs的水平或激活CB受体可减少Aβ沉淀，从而改善认知功能及学习记忆 [<xref ref-type="bibr" rid="hanspub.35419-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.35419-ref8">8</xref>]。2-AG通过激活过氧化物酶体增殖物激活型受体γ增强低密度脂蛋白受体相关蛋白1的表达以促进Aβ从脑入血的目的 [<xref ref-type="bibr" rid="hanspub.35419-ref9">9</xref>]，CB受体激活可增强Aβ通过血脑屏障转运，并阻止Aβ再次入脑 [<xref ref-type="bibr" rid="hanspub.35419-ref6">6</xref>]。CB2受体的激活可增强星型胶质细胞、小胶质细胞及巨噬细胞清除AD患者体内的Aβ的能力 [<xref ref-type="bibr" rid="hanspub.35419-ref10">10</xref>]。在大脑中被Aβ激活的小胶质细胞和星形胶质细胞进一步诱导促炎因子的产生和释放。2-AG通过激活CB1受体抑制ERK1/2-NF-κB-环氧合酶-2信号转导途径拮抗Aβ引起的海马神经元变性和凋亡 [<xref ref-type="bibr" rid="hanspub.35419-ref11">11</xref>]，另一种eCBs AEA亦可保护神经元免于Aβ的氧化损伤。小胶质细胞可增强Aβ清除和吞噬，但随着AD病情的恶化，由于小胶质细胞持续产生促炎因子丧失其清除Aβ的能力。研究发现CB2受体激动剂可抑制Aβ诱导的小胶质细胞激活，并恢复小胶质细胞清除Aβ的能力 [<xref ref-type="bibr" rid="hanspub.35419-ref12">12</xref>]。炎症会造成老年人的学习记忆和认知功能的损害，因此抑制炎症能抑制AD患者的认知功能的损害。研究表明CB1受体的激活能明显改善认知功能，但在AD的晚期给予CB1受体激动剂却加重Aβ诱导的神经元死亡，可能与抑制剩余的神经元活性有关 [<xref ref-type="bibr" rid="hanspub.35419-ref3">3</xref>]。急性给予CB受体激动剂会引起保留记忆的缺失，而CB1受体抑制剂能提高巩固空间记忆 [<xref ref-type="bibr" rid="hanspub.35419-ref13">13</xref>]。研究表明长期慢性给予CB2受体激动剂可显著减少认知功能的损害 [<xref ref-type="bibr" rid="hanspub.35419-ref14">14</xref>]。上述研究揭示eCBs对Aβ的保护作用是通过抗炎、抗氧化应激损伤及抗细胞凋亡来实现的。</p><p>Tau蛋白可由tau蛋白激酶I高度磷酸化后失去活性，从而产生神经细胞毒性。糖原合成酶激酶3β (glycogen synthase kinase 3β, GSK3β)是tau蛋白的磷酸化关键酶，目前认为GSK3β是迟发型AD的高危险因子，因此抑制其磷酸化可用于AD的治疗。在整体动物急性给予大麻素可通过激活CB1受体促进GSK3β磷酸化表达，导致tau蛋白磷酸化降低 [<xref ref-type="bibr" rid="hanspub.35419-ref15">15</xref>]，CB2受体激动剂亦可抑制tau蛋白的磷酸化。大麻的有效成分四氢大麻酚呈剂量依赖性激活蛋白激酶B导致GSK3β失活，该效应是由CB1受体和磷酸肌醇3激酶介导。研究发现磷酸肌醇3激酶/蛋白激酶B信号途径尚能通过增强抗凋亡蛋白的表达及抑制凋亡前体蛋白的表达来促进神经细胞功能的恢复 [<xref ref-type="bibr" rid="hanspub.35419-ref15">15</xref>]。综上所述，大麻素对tau蛋白的抑制作用与CB受体介导的GSK3β的磷酸化水平密切相关。</p></sec><sec id="s6"><title>4. eCBs系统对PD的保护作用</title><p>PD的病理特征主要表现为黑质多巴胺能神经元及其它含色素的神经元大量丢失和残留的神经细胞胞质内出现嗜酸性包涵体(亦称为路易小体)。</p><p>研究发现eCBs可调节基底神经节的生理功能。CB1受体在纹状体–黑质和纹状体–苍白球GABA能抑轴突末端、丘脑底核投射至内侧苍白球/黑质网状部和致密部的谷氨酸能轴突末端广泛分布，CB1受体激活后影响GABA和谷氨酸的释放，多巴胺D2受体激活后释放AEA [<xref ref-type="bibr" rid="hanspub.35419-ref16">16</xref>]。瞬时受体电位香草酸亚型1 (transient receptor potential vanilloid 1, TRPV1)通道在黑质多巴胺能神经元中表达，AEA通过激活TRPV1通道调节神经递质的释放 [<xref ref-type="bibr" rid="hanspub.35419-ref17">17</xref>]。eCBs与谷氨酸、GABA及多巴胺的相互作用为eCBs用非多巴胺类药物治疗PD提供了理论依据。</p><p>eCBs可调节皮质与纹状体的突触可塑性发挥药理作用。在PD动物模型和患者中，纹状体和皮质运动区均有长时程增强和长时程抑制的损害，揭示突触可塑性的损害可能是PD的关键致病因素 [<xref ref-type="bibr" rid="hanspub.35419-ref18">18</xref>]。纹状体中间多极神经元去极化、胞内Ca<sup>2+</sup>浓度增加或D2受体激活等均可导致AEA的释放，CB1受体的激活诱导谷氨酸依赖的长时程抑制的产生 [<xref ref-type="bibr" rid="hanspub.35419-ref19">19</xref>]。由此可见，eCBs通过调制皮质–纹状体的长时程抑制在调节纹状体神经通路中起到重要作用。</p><p>在PD模型中CB1受体下调会抑制皮质–纹状体的eCBs-长时程抑制及突触去增强现象，认为皮质–纹状体eCBs-长时程抑制和突触去增强在神经退行性疾病的致病因素中具有重要作用。而且CB1受体激动剂对L-DOPA诱导的运动迟缓具有保护作用。在一项PD患者中应用大麻素治疗的研究显示，大麻素能改善运动迟缓、肌肉僵直和震颤等症状 [<xref ref-type="bibr" rid="hanspub.35419-ref20">20</xref>]，该研究揭示eCBs在PD治疗中具有重要意义。</p></sec><sec id="s7"><title>5. eCBs系统对ALS的保护作用</title><p>ALS是一种逐渐累及上、下运动神经元及其支配的头面部、躯干和四肢肌肉的慢性进行性神经退行性疾病。在临床经常表现为上、下运动神经元均受损的混合性瘫痪。但病因不明，可能与免疫、中毒、病毒感染等因素有关，部分病例还具有遗传特征。</p><p>迄今为止，eCBs对人类ALS患者的研究较少，eCBs系统之变化可部分反映此病的神经源性炎症的致病机理。目前未有ALS的动物模型能精确反映其病理特征。有研究揭示表达人SOD1突变的转基因小鼠的运动神经元变性与家族遗传性或散发的ALS病例在病理和细胞层面相似 [<xref ref-type="bibr" rid="hanspub.35419-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.35419-ref22">22</xref>]。现在hSOD1G93A的转基因小鼠是用于临床前测试治疗ALS的小鼠种系。该ALS模型小鼠的发病、进展过程和结果均接近罹患ALS的人类。</p><p>在ALS模型大鼠的研究发现，大麻素受体激动剂有助于缓解ALS的病情 [<xref ref-type="bibr" rid="hanspub.35419-ref23">23</xref>] [<xref ref-type="bibr" rid="hanspub.35419-ref24">24</xref>]，脊髓腰膨大部位的AEA和2-AG积聚，应该是与eCBs的防御机制密切有关 [<xref ref-type="bibr" rid="hanspub.35419-ref23">23</xref>]。文献报道在hSOD1G93A小鼠CB2的免疫活性未见增强，但在症状前阶段CB1受体表达减少，相反在有症状阶段其表达增强，该效应可能与纹状体的CB1受体上调有关 [<xref ref-type="bibr" rid="hanspub.35419-ref25">25</xref>] [<xref ref-type="bibr" rid="hanspub.35419-ref26">26</xref>]。</p><p>在ALS模型小鼠，大麻素的有效成分四氢大麻酚能延长小鼠的生存率和延迟运动损伤 [<xref ref-type="bibr" rid="hanspub.35419-ref27">27</xref>]，大麻素的激动剂则延缓病情进展，在脂肪酰胺水解酶基因敲除的ALS模型小鼠，增加的胞内AEA水平延长运动神经元的生存率，揭示eCBs对ALS小鼠有保护作用 [<xref ref-type="bibr" rid="hanspub.35419-ref23">23</xref>]。敲除CB1受体的ALS小鼠可延长其寿命，但并未增加运动神经元的生存率 [<xref ref-type="bibr" rid="hanspub.35419-ref23">23</xref>]。在罹患ALS之初后给予CB2激动剂可延缓病情 [<xref ref-type="bibr" rid="hanspub.35419-ref24">24</xref>]，表明CB2受体参与介导ALS的进展。鉴于eCBs对ALS模型小鼠有神经保护效应，并无精神方面的副作用，有理由相信eCBs有望成为防治疗ALS的新靶点。</p></sec><sec id="s8"><title>6. 小结与展望</title><p>eCBs系统治疗神经退行性疾病AD、PD及ALS的机制尚不明确，但eCBs系统在神经系统具有广泛分布和调节作用，为延缓此类神经退行性疾病提供重要依据。因此eCBs系统同AD、PD及ALS等神经退行性疾病之间的关系的进一步揭示，为探究AD、PD及ALS等神经退行性疾病的发病机制及其分子靶向干预治疗提供新的策略和希望。</p></sec><sec id="s9"><title>文章引用</title><p>朱时钰,陆永利,杨红卫. 内源性大麻素在神经退行性疾病中的作用研究进展 Review of Research Progress on Endocannabinoids in Neurodegenerative Diseases[J]. 国际神经精神科学杂志, 2020, 09(02): 20-25. https://doi.org/10.12677/IJPN.2020.92003</p></sec><sec id="s10"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.35419-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Ohno-Shosaku, T., Tanimura, A., Hashimotodani, Y., et al. (2012) Endocannabinoids and Retrograde Modulation of Synaptic Transmission. Neuroscientist, 18, 119-132. https://doi.org/10.1177/1073858410397377</mixed-citation></ref><ref id="hanspub.35419-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Xu, J. and Chen, C. (2015) Endocannabinoids in Synaptic Plasticity and Neuroprotection. Neuroscientist, 21, 152-168. 
https://doi.org/10.1177/1073858414524632</mixed-citation></ref><ref id="hanspub.35419-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">朱时钰, 杨红卫. 大麻素2型受体在帕金森病中的神经保护作用研究进展[J]. 生命的化学, 2018, 38(4): 529-533.</mixed-citation></ref><ref id="hanspub.35419-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Scotter, E.L., Abood, M.E. and Glass, M. (2010) The Endocannabinoid System as a Target for the Treatment of Neurodegenerative Disease. British Journal of Pharmacol-ogy, 160, 480-498.  
https://doi.org/10.1111/j.1476-5381.2010.00735.x</mixed-citation></ref><ref id="hanspub.35419-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, L., Wang, M., Bisogno, T., Di Marzo, V. and Alger, B.E. (2011) Endocannabinoids Generated by Ca2+or by Metabotropic Glutamate Receptors Appear to Arise from Different Pools of Diacylglycerol Lipase. PLoS ONE, 6, e16305.  
https://doi.org/10.1371/journal.pone.0016305</mixed-citation></ref><ref id="hanspub.35419-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Raskin, J., Cummings, J., Hardy, J., Schuh, K. and Dean, R.A. (2015) Neurobiology of Alzheimer’s Disease: Integrated Molecular, Physiological, Anatomical, Biomarker, and Cognitive Dimensions. Current Alzheimer Research, 12, 712-722. https://doi.org/10.2174/1567205012666150701103107</mixed-citation></ref><ref id="hanspub.35419-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Chen, R., Zhang, J., Wu, Y., et al. (2012) Monoacylglycer-ol Lipase Is a Therapeutic Target for Alzheimer’s Disease. Cell Reports, 2, 1329-1339. https://doi.org/10.1016/j.celrep.2012.09.030</mixed-citation></ref><ref id="hanspub.35419-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Schmöle, A.C., Lundt, R., Toporowski, G., Hansen, J.N., et al. (2018) Cannabinoid Receptor 2-Deficiency AmelioratesDisease Symptoms in a Mouse Model with Alzheimer’s Dis-ease-Like Pathology. Journal of Alzheimer’s Disease, 64, 379-392. https://doi.org/10.3233/JAD-180230</mixed-citation></ref><ref id="hanspub.35419-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Gauthier, A., Vassiliou, G., Benoist, F., et al. (2003) Adipocyte Low Density Lipoprotein Receptor-Related Protein Gene Expression and Function Is Regulated by Peroxisome Prolifera-tor-Activated Receptor γ. Journal of Biological Chemistry, 278, 11945-11953. https://doi.org/10.1074/jbc.M212989200</mixed-citation></ref><ref id="hanspub.35419-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Tolón, R.M., Núñez, E., Pazos, M.R., et al. (2009) The Activation of Cannabinoid CB2 Receptors Stimulates in Situ and in Vitro Beta-Amyloid Removal by Human Macrophages. Brain Research, 1283, 148-154. 
https://doi.org/10.1016/j.brainres.2009.05.098</mixed-citation></ref><ref id="hanspub.35419-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Chen, X., Zhang, J. and Chen, C. (2011) Endocanna-binoid 2-Arachidonoylglycerol Protects Neurons against β-Amyloid Insults. Neuroscience, 178, 159-168. https://doi.org/10.1016/j.neuroscience.2011.01.024</mixed-citation></ref><ref id="hanspub.35419-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Wu, J., Bie, B., Yang, H., et al. (2013) Activation of the CB2 Receptor System Reverses Amyloid-Induced Memory Deficiency. Neurobiology of Aging, 34, 791-804. https://doi.org/10.1016/j.neurobiolaging.2012.06.011</mixed-citation></ref><ref id="hanspub.35419-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Wolff, M.C. and Leander, J.D. (2003) SR141716A, a Cannabinoid CB1 Receptor Antagonist, Improves Memory in a Delayed Radial Maze Task. European Journal of Pharmacology, 477, 213-217.  
https://doi.org/10.1016/j.ejphar.2003.08.025</mixed-citation></ref><ref id="hanspub.35419-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Martin-Moreno, A.M., Brera, B., Spuch, C., et al. (2012) Prolonged Oral Cannabinoid Administration Prevents Neuroinflammation, Lowers Beta-Amyloid Levels and Im-proves Cognitive Performance in Tg APP 2576 Mice. Neuroinflammation, 9, 8. https://doi.org/10.1186/1742-2094-9-8</mixed-citation></ref><ref id="hanspub.35419-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Ozaita, A., Puighermanal, E. and Maldonado, R. (2007) Regula-tion of PI3K/Akt/GSK-3 Pathway by Cannabinoids in the Brain. Journal of Neurochemistry, 102, 1105-1114. https://doi.org/10.1111/j.1471-4159.2007.04642.x</mixed-citation></ref><ref id="hanspub.35419-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Giuffrida, A., Parsons, L.H., Kerr, T.M., et al. (1999) Dopa-mine Activation of Endogenous Cannabinoid Signaling in Dorsal Striatum. Nature Neuroscience, 2, 358-363. https://doi.org/10.1038/7268</mixed-citation></ref><ref id="hanspub.35419-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Marinelli, S, Di Marzo, V., Florenzano, F., Fezza, F., et al. (2007) N-Arachidonoyl-Dopamine Tunes Synaptic Transmission onto Dopaminergic Neurons by Activating Both Canna-binoid and Vanilloid Receptors. Neuropsychopharmacology, 32, 298-308. https://doi.org/10.1038/sj.npp.1301118</mixed-citation></ref><ref id="hanspub.35419-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">邹梓良, 查运红, 杨红卫. 内源性大麻素系统与帕金森病关系的研究进展[J]. 广东医学, 2015, 36(9): 1449-1451.</mixed-citation></ref><ref id="hanspub.35419-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Kreitzer, A.C. and Malenka, R.C. (2005) Dopamine Modulation of State Dependent Endocannabinoid Release and Long-Term Depression in the Striatum. Neuroscience, 25, 10537-10545.  
https://doi.org/10.1523/JNEUROSCI.2959-05.2005</mixed-citation></ref><ref id="hanspub.35419-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Venderova, K., Ruzicka, E., Vorisek, V. and Visnovsky, P. (2004) Survey on Cannabis Use in Parkinson’s Disease: Subjective Improvement of Motor Symptoms. Movement Disorders, 19, 1102-1106. https://doi.org/10.1002/mds.20111</mixed-citation></ref><ref id="hanspub.35419-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Wong, P., Pardo, C., Borchelt, D., et al. (1995) An Adverse Property of a Familial ALS-Linked SOD1 Mutation Causes Motor Neuron Disease Charac-terized by Vacuolar Degeneration of Mitochondria. Neuron, 14, 1105-1116. 
https://doi.org/10.1016/0896-6273(95)90259-7</mixed-citation></ref><ref id="hanspub.35419-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Bruijn, L., Becher, M., Lee, M., et al. (1997) ALS-Linked SOD1 Mutant G85R Mediates Damage to Astro-Cytes and Promotes Rapidly Progressive Disease with SOD1-Containing Inclusions. Neuron, 18, 327-338. 
https://doi.org/10.1016/S0896-6273(00)80272-X</mixed-citation></ref><ref id="hanspub.35419-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Bilsland, L.G., Dick, J.R., Pryce, G., et al. (2006) In-creasing Cannabinoid Levels by Pharmacological and Genetic Manipulation Delay Disease Progression in SOD1 Mice. FASEB Journal, 29, 29. https://doi.org/10.1096/fj.05-4743fje</mixed-citation></ref><ref id="hanspub.35419-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Kim, K., Moore, D.H., Makriyannis, A., et al. (2006) AM1241, a Cannabinoid CB2 Receptor Selective Compound, Delays Disease Pro-Gression in a Mouse Model of Amyotrophic Lateral Sclerosis. European Journal of Pharmacology, 542, 100-105. https://doi.org/10.1016/j.ejphar.2006.05.025</mixed-citation></ref><ref id="hanspub.35419-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Zhao, P., Ignacio, S., Beattie, E.C., et al. (2008) Altered Pre-symptom-Atic AMPA and Cannabinoid Receptor Trafficking in Motor Neurons of ALS Model Mice: Implications for Excitotoxicity. European Journal of Neuroscience, 27, 572-579. https://doi.org/10.1111/j.1460-9568.2008.06041.x</mixed-citation></ref><ref id="hanspub.35419-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Rossi, S., De Chiara, V., Musella, A., et al. (2010) Abnormal Sensitivity of Cannabinoid CB1 Receptors in the Striatum of Mice with Experimental Amyotrophic Lateral Sclerosis. Amyotrophic Lateral Sclerosis, 19, 1-8. 
https://doi.org/10.3109/17482960902977954</mixed-citation></ref><ref id="hanspub.35419-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Rothstein, J.D., Patel, S., Regan, M.R., et al. (2005) Be-ta-Lactam Antibiotics Offer Neuroprotection by Increasing Glutamate Transporter Expression. Nature, 433, 73-77. https://doi.org/10.1038/nature03180</mixed-citation></ref></ref-list></back></article>